how long does 5mg of bpc 157 last BPC-157 Cost 2026: Real Pricing Breakdown BPC-157 5 mg | >99%

This product is not among those included in ConsumerLab

Phase 2 and Phase 3 trial data Major clinical trials: Phase 2 (24-week trial, 2008): 203 obese participants Three dose groups: 0.25mg, 0.5mg, 1.0mg daily Placebo-controlled, randomized Primary outcome: Weight loss percentage Phase 2 results: Key findings: Dose-dependent weight loss 1mg dose: Average 23 lbs lost (starting weight ~220 lbs) Best responders: 15-20% weight loss Comparable to semaglutide 2.4mg But higher dropout due to side effects Phase 3 trials (planned but never completed): Intended for FDA approval Halted due to cardiovascular concerns Increased heart rate 5-10 bpm average Blood pressure elevation 2-5 mmHg Risk-benefit ratio questioned Development suspended 2010 Long-term data (limited): 1-year extension studies showed sustained loss Weight plateau at 6-9 months Some regain if discontinued No controlled trials beyond 1 year Safety concerns prevented longer studies Compare to semaglutide trials and tirzepatide results

5-Amino 1MQ is a small molecule designed to inhibit the enzyme Nicotinamide N-methyltransferase (NNMT), affecting metabolism, muscle growth, and fat accumulation processes

We also recommend testing for folate and ferritin (iron storage), and do a full blood count